The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell.

2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting task.

Furthermore, the Federal Reserve’s cautious approach toward interest rate cuts this year casts a long shadow of economic uncertainty, further intensifying the biotech sector’s inherent volatility and risk. Hence, it is best to me cautious and steer clear of these three biotech stocks.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Novavax (NVAX)

Source: vovidzha / Shutterstock.com

Novavax (NASDAQ:NVAX), a biotech firm dedicated to developing vaccines for severe infectious diseases, is currently navigating through testing times. Moreover, NVAX stock plummeting by over 58% in the past year, the company’s future appears uncertain.

Furthermore, the company has been caught in a dispute with GAVI, a vaccine alliance, over a hefty refund of roughly $700 million. GAVI is looking for a refund for the amount it spent on advance payments for Covid shots. Additionally, Novavax’s global credibility is under further scrutiny after a $47 million settlement in a lawsuit accusing it of overstating its vaccine production.

Financially, NVAX has witnessed its revenues drop by a 43.2% plunge in annual revenue, starkly underperforming the sector’s median growth of 6.4%. The picture darkens with a hefty $655 million operational deficit over the last year and a recent quarter showing a 74.5% drop in revenue year-over-year (YOY) to roughly $187 million.

Cassava Sciences (SAVA)

Source: Postmodern Studio / Shutterstock.com

Cassava Sciences (NASDAQ:SAVA) has been a popular biotech firm due to its much-talked about Alzheimer’s treatment called Simufilam. Over the past year, its stock has dipped by 10.5%, with concerns that its future depends on Simufilam’s success.

Adding to challenges in drug development, SAVA faces scrutiny over data integrity issues. Accusations have targeted its co-founder for skewing test results to favor Simufilam. This controversy has struck a blow to SAVA, hurting its credibility and amplifying concerns over its long-term positioning.

Furthermore, Cassava’s financial health raises alarms, as a net loss of $25.7 million marks a worrying increase from last year’s $20.3 million. This financial strain is further highlighted by a negative 53.94% return on common equity, contrasting with the sector’s median of negative 42.41%.